Using PET/MRI to Monitor Brain Inflammation
An Oberservational Study of Utility of TSPO-PET/MRI Using the Radiotracer ([18F]-DPA-714) in Surveillance of Neuroinflammation in the Central Nervous System
This study is testing how PET/MRI scans can help track brain inflammation in people with conditions like stroke, autoimmune encephalitis, and multiple sclerosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tongji Hospital Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06467773 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate central nervous system (CNS) inflammation by utilizing PET/MRI imaging techniques. It focuses on conditions such as ischemic stroke, autoimmune encephalitis, and multiple sclerosis, where inflammation plays a critical role. The study will monitor the inflammatory response driven by microglial cells, which are essential for diagnosing and treating CNS diseases. Participants will undergo PET-MRI scans using a specific radiotracer to assess inflammation levels in the brain and spinal cord.
Who should consider this trial
Good fit: Ideal candidates include individuals with a clinical diagnosis of ischemic stroke, autoimmune encephalitis, neuromyelitis optica spectrum disorders, or multiple sclerosis.
Not a fit: Patients with claustrophobia, metal implants, or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the diagnosis and treatment of various central nervous system diseases by providing better insights into inflammation.
How similar studies have performed: Other studies have shown promise in using PET/MRI for monitoring CNS inflammation, indicating that this approach is gaining traction in the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: -Clinical diagnosis of ischemic stroke, autoimmune ecephalitis, Neuromyelitis optica spectrum disorders, or multiple sclerosis, etc.al Exclusion Criteria: * Claustrophobia * Metal Implants * Pregancy * Breast-feeding * Renal insufficiency (GFR \< 60 mL/min/1.73m2) * Allergy or other contraindication to gadolinium-based MR contrast agent
Where this trial is running
Wuhan, Hubei
- Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology — Wuhan, Hubei, China (Recruiting)
Study contacts
- Principal investigator: Wei Wang, MD — Tongji Hospital
- Study coordinator: Luo-qi Zhou, MD
- Email: zhouluoqi@tjh.tjmu.edu.cn
- Phone: 86-27-83663337
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.